Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | GFER | P55789 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.40 |
| ▸ | RARA | P10276 | 2/20 | 0.40 |
| ▸ | RARB | P10826 | 2/20 | 0.40 |
| ▸ | RARG | P13631 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972365 | 0.89 | MEN1 (0.79) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL2710580 | 0.86 | MEN1 (0.76) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL549446 | 0.85 | MEN1 (0.73) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL548708 | 0.85 | MEN1 (0.73) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL3756585 | 0.84 | MEN1 (0.72) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL14829735 | 0.83 | MEN1 (0.71) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL14829242 | 0.83 | MEN1 (0.71) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL2710154 | 0.83 | MEN1 (0.71) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL6449310 | 0.83 | MEN1 (0.71) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL14829050 | 0.83 | MEN1 (0.71) | MEN1KMT2AGAAPOLBGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009111611-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ISLET AMYLOID POLYPEPTIDE (IAPP) ACCUMULATION IN DIABETES | PROTEOTECH INC. (US) | 2009-09-11 | — | — | WO | claimed |
| CN-119504482-A | Synthesis and anti-tumor property research of adamantane drug small molecules modified by different groups | 长春工业大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-119504482-A | Synthesis and anti-tumor property research of adamantane drug small molecules modified by different groups | 长春工业大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-118515580-A | Synthesis and anti-tumor activity research of novel adamantane structure-containing drug small molecules | 长春工业大学 | 2024-08-20 | — | — | CN | disclosed |
| US-20170008838-A1 | COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES | PROTAMED INC (US) | 2017-01-12 | — | — | US | disclosed |
| US-8916598-B2 | Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies | PROTEOTECH INC (US) | 2014-12-23 | — | — | US | disclosed |
| EP-2328417-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF beta-AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20120035230-A1 | Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | PROTAMED, INC. | 2012-02-09 | — | — | US | disclosed |
| US-8084650-B2 | Adamantane derivative, resin composition containing same, and optoelectronic member and sealing agent for electronic circuit using those | IDEMITSU KOSAN CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| CN-102170787-A | Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies | PROTEOTECH INC | 2011-08-31 | — | — | CN | disclosed |
| EP-2328417-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF beta-AMYLOID DISEASES AND SYNUCLEINOPATHIES | Proteotech Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100298491-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION CONTAINING SAME, AND OPTOELECTRONIC MEMBER AND SEALING AGENT FOR ELECTRONIC CIRCUIT USING THOSE | IDEMITSU KOSAN CO., LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| WO-2010039308-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF β-AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009111611-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ISLET AMYLOID POLYPEPTIDE (IAPP) ACCUMULATION IN DIABETES | PROTEOTECH INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-1985616-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION CONTAINING SAME, AND OPTOELECTRONIC MEMBER AND SEALING AGENT FOR ELECTRONIC CIRCUIT USING THOSE | Idemitsu Kosan Co., Ltd. (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298491-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION CONTAINING SAME, AND OPTOELECTRONIC MEMBER AND SEALING AGENT FOR ELECTRONIC CIRCUIT USING THOSE | AOC1, ASIC1, ICAM1 | MEN1 2523/4885KMT2A 4159/4885GAA 1740/4885 |
| US-20120035230-A1 | Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | SNCA, PARK7, HTT | MEN1 3368/4885KMT2A 4165/4885GAA 19/4885 |
| US-20170008838-A1 | COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES | PSEN2, PSEN1, MAPT | MEN1 4471/4885KMT2A 3777/4885GAA 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.